Novartis Drug Kisqali Boosts Survival Rate Of Young Breast Cancer Patients Clinical trials featuring Novartis' Kisqali revealed the potential of the drug to extend the life of breast cancer patients. Results showed that when Kisqali was used along with hormone therapy, it could increase survival rates by 70.2 percent. by Ted Ranosa